Home > Boards > US Listed > Biotechs > Verastem (VSTM)

VSTM 05/10/19 07:46am Verastem analyst commentary at BTIG

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 16
Posts 1,187
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire - 6/17/2019 7:00:00 AM
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire - 5/30/2019 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2019 5:23:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:22:02 PM
Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference Business Wire - 5/16/2019 7:00:00 AM
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study Business Wire - 5/15/2019 5:16:00 PM
Verastem Oncology Reports First Quarter 2019 Financial Results Business Wire - 5/9/2019 4:05:00 PM
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 Business Wire - 5/2/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2019 4:22:15 PM
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility Business Wire - 4/23/2019 4:05:00 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/8/2019 4:13:23 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 4/4/2019 4:05:00 PM
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire - 4/2/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 4:14:21 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/18/2019 6:10:17 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/12/2019 4:28:34 PM
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments Business Wire - 3/12/2019 4:08:00 PM
Verastem Oncology to Present at Upcoming Investor Conferences Business Wire - 3/12/2019 7:00:00 AM
Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Mali... Business Wire - 3/7/2019 5:01:00 PM
Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progresse... Business Wire - 3/4/2019 7:00:00 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 3/1/2019 4:49:00 PM
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019 Business Wire - 2/26/2019 7:00:00 AM
Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire - 2/21/2019 7:00:00 AM
CORRECTING and REPLACING Verastem Oncology Announces Key Management Appointments Business Wire - 2/20/2019 8:43:00 AM
Verastem Oncology Announces Key Management Appointments Business Wire - 2/20/2019 7:00:00 AM
stockguard   Friday, 05/10/19 09:16:04 AM
Re: None
Post # of 394 
VSTM 05/10/19 07:46am Verastem analyst commentary at BTIG Verastem price target lowered to $8 from $17 at BTIG. BTIG analyst Robert Hazlett lowers his price target on Verastem to $8 after its Q1 results featured a more modest 2019 sales guidance for Copiktra at $10M-$12M - below his estimate of $50M. The analyst contends that the guidance suggests overcoming the challenges of Copiktra launch will take longer than anticipated, adding that he is also removing the possibility of M&A from his model. Hazlett keeps his Buy rating on the stock however and still believes in Copiktra's potential to "materially disrupt the tumor microenvironment.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist